Document Type

Article

Publication Date

6-1-2019

Comments

This article has been peer reviewed. It is the author’s final published version in Indian Journal of Ophthalmology, Volume 67, Issue 6, June 2019, Pages 740-754.

The published version is available at https://doi.org/10.4103/ijo.IJO_866_19. Copyright © Manjandavida et al.

Abstract

Intra-arterial chemotherapy (IAC), also known as superselective ophthalmic artery chemotherapy or chemosurgery, is currently widely accepted as one of the primary treatment modalities for intraocular retinoblastoma worldwide. Following the introduction of the technique in 1998, IAC has evolved over the past decades to be safer and more effective. Accumulated evidence shows that IAC is more effective in providing eye salvage in group D and E retinoblastoma as compared to conventional systemic intravenous chemotherapy (IVC). In contrast to IVC, IAC has the added benefits of reduced overall treatment duration and minimal systemic toxicity. This review provides a comprehensive update on the history, technique, indications, contraindications, and outcome of IAC. We have also identified the strengths, weaknesses, opportunities and threats (SWOT analysis) of the technique in this review.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

PubMed ID

31124482

Language

English

Download

Included in

Ophthalmology Commons

Share

COinS